RA190 is a proteasome-associated deubiquitinase inhibitor primarily studied for its potential in cancer therapy. It works by inducing the accumulation of polyubiquitinated proteins, leading to proteotoxic stress and apoptosis in cancer cells. This mechanism makes it a promising candidate for targeting malignancies that are resistant to conventional treatments. RA190 has shown efficacy in preclinical studies against various cancer types, including ovarian, cervical, and multiple myeloma, by selectively killing cancer cells while sparing normal cells. Its ability to disrupt protein homeostasis offers a novel approach to overcoming drug resistance, making it a valuable tool in oncology research and therapeutic development.